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Background. Sequencing technologies and techniques have seen remarkable transformation and innovation that have signifi-
cantly affected sequencing capability. Data analyses have replaced sequencing as the main challenge. This paper provides an overview 
on applying next-generation sequencing (NGS) and analysis and discusses the benefits and challenges. In addition, this document 
shows results from using NGS and bioinformatics tools to screen for β-lactamase genes and assess the epidemiological structure of 
Escherichia coli– and Klebsiella pneumoniae–causing bloodstream (BSIs) and urinary tract (UTIs) infections in patients hospitalized 
in the United States during the SENTRY Antimicrobial Surveillance Program for 2016.
Methods. A total of 3525 isolates (2751 E. coli and 774 K. pneumoniae) causing BSIs (n = 892) and UTIs (n = 2633) in hospital-
ized patients in the United States were included. Isolates were tested for susceptibility by broth microdilution, and those that met a 
minimum inhibitory concentration (MIC)–based screening criteria had their genomes sequenced and analyzed.
Results. A total of 11.6% and 16.1% of E. coli–causing UTIs and BSIs, respectively, met the MIC-based criteria, whereas 11.0% 
and 13.7% of K. pneumoniae isolates causing UTIs and BSIs, respectively, met the criteria. Among E. coli, blaCTX-M variants (87.6% 
overall) prevailed (60.5% of CTX-M group 1 and 26.9% of group 9). A total of 60.3% of K. pneumoniae isolates carried blaCTX-M 
variants (52.7% and 7.6% of groups 1 and 9, respectively). Two E. coli (0.6%) and 13 K. pneumoniae (12.9%) isolates harbored blaKPC. 
Among KPC-producing K. pneumoniae (2 from BSIs and 11 from UTIs), 84.6% (11/13) were ST258 (CC258). Seventeen and 38 
unique clonal complexes (CCs) were noted in E. coli that caused BSIs and UTIs, respectively, and CC131 (or ST131) was the most 
common CC among BSI (53.6%) and UTI (58.2%) isolates. Twenty-three and 26 CCs were noted among K. pneumoniae–causing 
BSIs and UTIs, respectively. CC258 (28.3%) prevailed in UTI pathogens, whereas CC307 (15.0%) was the most common CC among 
BSI isolates.
Conclusions. This study provides a benchmark for the distribution of β-lactamase genes and the population structure informa-
tion for the most common Enterobacteriaceae species responsible for BSIs and UTIs in US medical centers during the 2016 SENTRY 
Program.
Keywords. genome; high-throughput; MLST; resistance.
Several surveillance studies conducted in the last few decades 
collected and generated massive amounts of data, including 
prevalence of pathogens causing hospital and community infec-
tions and susceptibility information for monitoring antimicro-
bial resistance. In general, the vast majority of these studies 
have generated phenotypic information associated with bac-
teria and fungi, from organism identification to antimicrobial 
susceptibility profiles. Although small local surveillance studies 
have long utilized various molecular methodologies for fur-
ther characterization of organisms, large-scope investigations 
introduced the use of molecular techniques in a more gradual 
manner, mostly due to feasibility issues. Eventually, when appli-
cable, large surveillance studies utilized molecular techniques 
to investigate specific phenotypes observed in subsets of isolates 
within a collection of surveillance strains [1–5].
In the past 2 decades, large surveillance studies used to apply 
singleplex and multiplex polymerase chain reaction (PCR) assays 
for characterizing clinically relevant pathogens of interest respon-
sible for human infections. These reactions were used for several 
applications, including screening of resistance and virulence genes, 
typing, and serotyping of organisms [6–15]. With the availability of 
a “first-generation” DNA sequencing method (Sanger sequencing), 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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PCR amplicon sequencing was incorporated as an additional step 
after PCR assays to confirm and identify gene variants [5, 16]. The 
Sanger method comprises the process of selectively incorporat-
ing chain-terminating dideoxynucleotides by DNA polymerase 
during in vitro DNA replication; it was commercialized by Applied 
Biosystems (Foster City, CA). Although these techniques provide 
good and reliable results, they tend to be very time-consuming and 
labor-intensive. Currently, a number of automated methods can 
be utilized to further characterize organisms in a higher-through-
put and friendly manner [17–22]. Despite the advantages of 
higher-throughput next-generation sequencing methods, Sanger 
sequencing is still used for specific purposes.
Since the first bacterial genome sequence was completed 2 
decades ago [23], sequencing technologies and techniques have 
undergone remarkable transformation and innovation [23, 24]. 
Technological advances have significantly affected sequencing 
capability and, consequently, decreased the cost per megab-
ase of sequence, becoming economically feasible for scientific 
research, clinical diagnostics, and surveillance programs [24]. 
Thus, sequencing has not been the recent limitation, but analyz-
ing the gigabytes of data generated and providing accurate and 
meaningful interpretations have become limitations. In addi-
tion, sequence data and analyses need to provide translational 
information that can provide actionable items in real time, such 
as information to minimize the dissemination of clones or resis-
tance genes, genomic surveillance, and the detection and control 
of hospital outbreaks [25, 26].
This paper provides an overview of the application of bacte-
rial genome sequencing and analysis in large surveillance pro-
grams, among other settings, and discusses the benefits and 
challenges associated with the detection of resistance mech-
anisms, epidemiology typing, serotyping, and other means of 
molecular bacterial characterization. In addition, this docu-
ment offers a study example of the application of the combina-
tion of next-generation sequencing (NGS) and bioinformatics 
tools to screen for β-lactamase genes and to assess the epide-
miologic structure of Escherichia coli and Klebsiella pneumo-
niae that produce extended-spectrum β-lactamases (ESBLs), 
including carbapenemases, causing bloodstream (BSIs) and 
urinary tract (UTIs) infections in patients hospitalized in the 
United States during the SENTRY Antimicrobial Surveillance 
Program for 2016.
The Power of Genome Sequencing and Bioinformatics Tools
Phenotypic Prediction
Some studies have published promising results demonstrat-
ing that phenotypic profiles can be predicted based on the 
presence of certain genetic determinants. These studies have 
empirically demonstrated that predicting susceptibility and 
resistance using high-throughput genome sequencing and bio-
informatics data analysis may be feasible or potentially feasible 
for Staphylococcus aureus, Enterobacteriaceae, Pseudomonas 
aeruginosa, Campylobacter spp., Helicobacter pylori, Neisseria 
gonorrhoeae, and Mycobacterium tuberculosis [27].
The causal relationship between the presence of any given 
gene(s) and the respective phenotype has been well established 
for genes, such as β-lactamase genes, vancomycin resistance genes 
(eg, vanA), macrolide-lincosamide-streptogramin B (MLSB), flu-
oroquinolones (acquired genes and mutations in the quinolone 
resistance–determining region [QRDR]), pleuromutilins, oxaz-
olidinones, and tetracycline, to name a few. The pre-established 
knowledge of resistance genes and respective phenotypes allows 
for the possibility of predicting these phenotypes based on geno-
typic data. However, resistance phenotypes associated with glyco-
peptides, lipoglycopeptides, and cyclic lipopeptides, for instance, 
may involve multiple and/or complex resistance mechanisms that 
are yet not very well understood and may remain a challenge for 
genotypic detection and, consequently, phenotypic prediction. In 
addition, up- or downregulation of intrinsic genes can also pres-
ent challenges for phenotype prediction.
A recent investigation utilized a machine-learning approach 
to predict the susceptibility phenotype in M. tuberculosis [28]. 
This approach could have the potential to better predict those 
resistance phenotypes associated with complex and multiple 
mutations, such as those linked with or close to the drug target 
site, alterations in porin channels (being just a minimal num-
ber of single nucleotide polymorphisms [SNPs] or a disruption 
due to an insertion sequence), alterations in promoter regions, 
or repressor genes. However, it is conceivable that phenotypic 
and genotypic information will need to be generated continu-
ously, at least at a global level, to provide training data, so the 
“learning” of mechanisms to old and new drugs remains con-
stant. This information would be utilized to maintain a database 
available to any data analysis center or clinical laboratory.
Genome Sequencing and Bioinformatics in Clinical Trials
Many studies were performed to molecularly characterize 
clinical trial isolates to determine the presence of resistance 
genes, virulence genes, and/or typing information [29–35]. 
The latter can be utilized to identify lineages, or the genetic 
background of strains, recovered from enrolled patients. 
When pathogens from the same species are recovered from 
clinical specimens collected during multiple study visits, typ-
ing methods are applied to suggest cases of persistent infection 
or re-infection. Proven re-infection cases have the potential to 
alter the efficacy data for the investigational and comparator 
agents [36]. Moreover, the information obtained from char-
acterized resistance mechanisms among clinical trial isolates 
can be utilized to form genetic subsets of isolates, which can 
provide a more granular analysis of the in vivo efficacy and in 
vitro activity data. It is also important to mention that patho-
gens (baseline and follow-up isolates) that develop a resistance 
phenotype to the study drug during treatment can be investi-
gated to determine the resistance mechanisms [36].
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NGS and proper data analysis more recently have been 
applied to characterize a particular microbiome (eg, the gut 
microbiome) using metagenomics. Two approaches can be uti-
lized: shotgun metagenomics or targeted-amplicon sequencing. 
Shotgun metagenomics attempts to sequence the entire genetic 
content present in a sample, and targeted-amplicon sequenc-
ing represents a more biased approach that targets a particular 
group of microorganisms [37]. Because antimicrobial therapy 
can affect normal human flora, some pharmaceutical compa-
nies have studied the impact of investigational drugs on the gut 
flora. DNA can be sequenced directly from human clinical sam-
ples by metagenomics sequencing. This approach can identify 
and quantify organisms present in human samples and then 
compare the effect of the investigational and comparator agents 
on the intestinal flora during pre- and post-treatment periods, 
as well as the effect of different therapeutic regimens [38, 39].
Another area of possible interest during drug development 
would be a metagenomics investigation of all possible patho-
gens present in a given human clinical sample (eg, urine, 
sputum). NGS-based methods can offer a relatively unbiased 
approach for pathogen detection and quantification. Clinical 
samples collected pre- and post-treatment from patients who 
failed therapy can be investigated by metagenomics to detect 
organisms. This approach may help us understand if the pres-
ence of other uncultured organisms or species not detected by 
current conventional microbiology laboratory methods, includ-
ing those that can be refractory to the drug therapy being used, 
can explain poor clinical outcomes [40].
Challenges of Sequencing and Data Analysis
Powerful high-throughput genome sequencing has opened 
doors for massive DNA sequencing. Many current sequencing 
methodologies can be optimized and standardized in a protocol 
to be utilized for several species, facilitating implementation. In 
contrast, data analysis represents a challenge and, in general, 
requires bioinformatics knowledge to perform the various steps 
needed to answer any given question(s) [41, 42]. Many software 
programs are available online, and several options can be cho-
sen to perform a single step of the process; each has its pros 
and cons [24]. Moreover, any in-depth analysis also requires 
scientific knowledge of genomic features and the biological 
background of the organism(s) under investigation to properly 
interpret results [42]. However, the ultimate goal would be to 
obtain a bioinformatics pipeline that would process the raw 
data and provide information in real time.
Regardless of software or the combination of software pro-
grams employed, the use of quality control (QC) criteria 
remains crucial for any laboratory process. Each sequencing 
methodology has its own QC metrics to ensure the quality of 
the sequencing data, and this does not enable the use of a sin-
gle and uniform set of QC parameters [43]. Moreover, different 
downstream applications would require different levels of QC 
parameters and metrics, such as SNP analysis from screening 
resistance/virulence genes, as the former requires greater cover-
age and sequencing for data analysis than the latter. In addition 
to the set of QC parameters related to the sequencing data, a set 
of QC strains with known genotypes associated with the down-
stream application should be used systematically to ensure that 
all steps from DNA extraction to data analysis are acceptable.
Using a database containing curated resistance/virulence 
genes is essential for proper detection, identification, and inter-
pretation of data. Databases need to be constantly updated to 
minimize the possibility of not detecting genes recently dis-
covered. A  number of databases are freely available, such as 
ResFinder, CARD, ARDB, MEGARes, ARG-ANNOT, and 
SSTAR, or a combination of databases (eg, JMI bioinformatics 
pipeline) [44–47]. In general, genetic markers and their respec-
tive annotations have not been standardized, and similar genes 
can have different annotations from database to database. As 
alluded to earlier, the organism’s biological background is cru-
cial for properly interpreting results. These high-throughput 
NGS and screening tools are very sensitive in detecting gene 
determinants, and these systems and databases will not indi-
cate the location (chromosomal, plasmid, or both), relevance, 
or association of gene(s) with any resistance phenotypes. Many 
resistance genes in the databases described here are chromo-
somally located and ubiquitous to several organisms and, when 
expressed in low levels, may not necessarily cause resistance 
phenotypes, or resistance may be limited to certain drugs 
within a class. Thus, the presence of an intrinsic gene may not 
be relevant for certain species–drug combinations, but poten-
tially may be important in others. To complicate things further, 
an isolate can display a resistance phenotype when such intrin-
sic genes are overexpressed due to alterations in the promoter 
region, insertion of a promoter upstream, and/or gene mobi-
lization into multicopy plasmids [48–57]. Therefore, certain 
genes detected in some species require careful interpretation.
Many organisms express resistance phenotypes due to over-
expression of intrinsic systems (efflux pumps), decreased or 
null expression of other alterations (porin channels needed 
for antimicrobial cell entry), and/or drug target  alterations 
[58–68]. The complete molecular characterization of resistance 
mechanisms in some species–drug class combinations requires 
quantifying certain cell components and/or sequencing and 
analyzing drug targets. In addition, drug targets need to be 
known, as well as whether any alterations in close or distal loca-
tions of the drug target affect binding [69–76]. Mutations caus-
ing frame-shift alterations or a premature stop codon within 
genes encoding for porin membranes (eg, OmpK35, OmpC) are 
simpler to interpret and less subjective. However, the interpre-
tation of mutations within housekeeping genes or drug target 
sequences is challenging and may require complex experiments 
to link any given alterations with a resistance phenotype. Also, 
the sequencing analysis requires the use of proper reference 
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sequences from organisms susceptible to the drug and/or class 
of drugs being analyzed. Ideally, the reference strain should 
belong to the same lineage as the query isolate in order to min-
imize the detection and report of less relevant polymorphisms.
METHODS
Organism Collection
A total of 3525 isolates causing BSIs (n  =  892) and UTIs 
(n  =  2633) in hospitalized patients in the United States were 
collected as part of the SENTRY Antimicrobial Surveillance 
Program. In total, 2751 E. coli (601 and 2150 isolates responsi-
ble for BSIs and UTIs, respectively) and 774 K. pneumoniae (291 
and 483 isolates responsible for BSIs and UTIs, respectively) 
were included. These isolates were consecutively collected (1 per 
patient) from 81 sites located in 36 states in 9 US census divi-
sions and were submitted to JMI Laboratories (North Liberty, 
IA) as part of the 2016 SENTRY Program. Isolates were initially 
identified by the participating laboratory, and identifications 
were confirmed at JMI Laboratories using matrix-assisted laser 
desorption ionization-time of flight mass spectrometry (Bruker 
Daltonics, Bremen, Germany) and genome sequencing.
Susceptibility Testing
Isolates were tested for susceptibility by the broth microdi-
lution method using cation-adjusted Mueller-Hinton broth. 
Susceptibility testing was performed at a central reference labo-
ratory (JMI Laboratories) according to Clinical and Laboratory 
Standards Institute (CLSI) methods [77, 78]. Manufacturing of 
broth microdilution minimum inhibitory concentration (MIC) 
panels (JMI Laboratories) and quality control practices fol-
lowed CLSI guidelines [77, 78].
Screen for β-Lactamase Genes by NGS and Bioinformatics Analysis
Isolates displaying elevated MIC results (≥2  mg/L) for ceftri-
axone, aztreonam, ceftazidime, and/or imipenem/meropenem 
were selected. A total of 11.6% (n = 249) and 16.1% (n = 97) of 
E. coli–causing UTIs and BSIs, respectively, met the MIC-based cri-
teria, whereas 11.0% (n = 53) and 13.7% (n = 40) of K. pneumoniae 
isolates causing UTIs and BSIs, respectively, met the criteria (data 
not shown). Total genomic DNA was extracted using the Thermo 
Scientific KingFisher Flex Magnetic Particle Processor (Cleveland, 
OH), which was used as input material for library construction. 
DNA libraries were prepared using the NexteraXT library con-
struction protocol (Illumina, San Diego, CA) following the manu-
facturer’s instructions and were sequenced on a MiSeq Sequencer 
(JMI Laboratories). FASTQ format sequencing files for each sam-
ple set were assembled independently using de novo assembler 
SPAdes 3.9.0, and a JMI Laboratories–designed software workflow 
was applied to the assembled sequences to align against a database 
containing known β-lactamase-encoding genes.
Epidemiology Typing
The same JMI Laboratories–designed software analysis work-
flow utilized for screening β-lactamase-encoding genes was 
employed on assembled genomes to identify and extract 
previously defined sets of 7 housekeeping gene fragments 
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Figure 1. Overall distribution of β-lactamase-encoding genes detected in Escherichia coli (A) and Klebsiella pneumoniae (B) causing urinary tract infections or bloodstream 
infections. Percentages obtained from total number of E. coli (346) or K. pneumoniae (93) as denominators. Chromosomal AmpC defined by the overexpression of AmpC; 
unknown defined as the lack of any β-lactamase screened during the study.
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(∼500  bp) for multilocus sequence typing (MLST) assign-
ment. Briefly, once extracted, each fragment was compared 
with known allele variants for each locus (housekeeping 
gene) on the respective MLST website (http://bigsdb.pasteur.
fr/klebsiella/ or http://enterobase.warwick.ac.uk/species/
ecoli). An allele sharing 100% genetic identity with a known 
variant received its numeric designation, and a 7-number 
sequence (1 for each housekeeping gene) formed an allelic 
profile, defined as sequence types (STs). ST profiles shar-
ing 100% genetic identity in at least 6 of 7 MLST loci were 
grouped into a clonal complex (CC), named after its pre-
sumed ancestral genotype. Isolates containing alleles that did 
not match an existing sequence in the MLST database were 
submitted/deposited in the respective database for allele and 
ST assignments.
RESULTS
In general, most E. coli (88.2% [305]) responsible for UTIs or 
BSIs that met the MIC-based screening criteria carried ESBL-
encoding genes (99.3% [303] of CTX-M, 0.3% [1] of SVH-12, 
and 0.3% [1] of TEM-19), followed by isolates associated with 
AmpC (9.2% [32]), either carrying plasmid AmpC (81.3% 
[26] of CMY-2, 3.1% [1] of CMY-42, or 3.1% [1] of DHA-1) 
or showing overexpression of the chromosomal AmpC (12.5% 
[4]). A total of 2.0% (n = 7) of E. coli did not show any of the 
β-lactamase genes investigated and were assigned here as 
unknown. Two (0.6%) E. coli clinical isolates harbored 1 each of 
the Klebsiella pneumoniae carbapenemase (KPC)–2 and KPC-
3-encoding genes. In addition, among E. coli isolates carrying 
blaCTX-M variants, CTX-M group 1 (60.5% overall or 69.3% 
within CTX-M genes) and group 9 (26.9% overall or 30.7% 
within CTX-M genes) prevailed (Figure 1A).
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Figure 2. Distribution of clonal complexes among Escherichia coli isolates recovered from urinary tract infections (outer circle) and bloodstream infections (inner circle).
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Among K. pneumoniae isolates responsible for UTIs or BSIs 
that met the MIC-based screening criteria, 75.3% (n = 70) car-
ried ESBL-encoding genes (80.0% [56] of CTX-M, 18.6% [13] 
of SVH variants, and 1.4% [1] of OXA-9), whereas 4.4% (n = 4) 
had plasmid AmpC (2.2% [2] of CMY-2, 1.1% [1] of FOX-5, or 
1.1% [1] of DHA-1). A total of 12.9% of K. pneumoniae clinical 
isolates harbored KPC-encoding genes (9 KPC-3 and 3 KPC-2). 
A total of 7.5% (n = 7) of K. pneumoniae isolates did not show 
any of the β-lactamase genes investigated. Among K. pneumo-
niae isolates, 52.7% (or 87.5% within CTX-M) and 7.6% (or 
12.5% within CTX-M) of blaCTX-M variants belonged to groups 1 
and 9, respectively (Figure 1B).
Among KPC-producing K. pneumoniae (2 from BSI and 11 
from UTI), 84.6% (11/13) were ST258 (CC258). Seventeen and 
38 unique CCs were noted in E.  coli–causing BSIs and UTIs, 
respectively, and CC131 (or ST131) was the most common CC 
among BSI (53.6%) and UTI (58.2%) E. coli isolates (Figure 2). 
Twenty-four and 26 CCs were noted among K.  pneumoniae 
isolates causing BSIs and UTIs, respectively. CC258 (28.3%; all 
but 1 ST1326 were ST258) prevailed in UTI pathogens, whereas 
CC307 (15.0%) was the most common CC among BSI isolates 
(Figure 3).
Among E.  coli isolates, the majority of blaCTX-M-15 (70.3%) 
were detected within ST131 isolates, with similar occurrences 
among those causing BSIs (68.4%) and UTIs (71.1%) (data not 
shown). Most ST131 E. coli isolates causing BSIs carried blaCTX-M 
genes belonging to CTX-M group 1 (75.0%), and a small per-
centage of genes belonged to group 9 (17.3%) (Figure 4). ST131 
E. coli isolates causing UTIs had a greater number of blaCTX-M 
genes belonging to CTX-M group 9 (30.4%) when compared 
with isolates causing BSIs (17.3%) (Figure 4).
DISCUSSION
The study presented here illustrates the applicability of NGS and 
proper data analysis to evaluate the presence and distribution 
of β-lactamase-encoding genes and bacterial lineages among 
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Figure 3. Distribution of clonal complexes among Klebsiella pneumoniae isolates recovered from urinary tract infections (outer circle) and bloodstream infections (inner 
circle).
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specific groups of organisms causing infections in humans. 
E.  coli and K.  pneumoniae are prevalent Enterobacteriaceae 
causing a variety of infection types in hospital and commu-
nity settings. The data clearly show the dissemination of E. coli 
ST131 isolates in the United States, regardless of infection site, 
whereas the population structure of K. pneumoniae was more 
heterogeneous. In addition, the data confirm the dominance of 
group 1 CTX-M-encoding genes among E. coli, E. coli ST131, 
and K. pneumoniae; however, the data presented here may also 
suggest that genes belonging to CTX-M group 9 may be spread-
ing among UTI E. coli isolates. A recent clinical trial compar-
ing piperacillin-tazobactam and meropenem for treating BSIs 
caused by E.  coli or Klebsiella spp. that were nonsusceptible 
to ceftriaxone and susceptible to piperacillin-tazobactam also 
reported the dominance of blaCTX-M genes (83.5%), especially 
blaCTX-M-15 (54.5%) [35].
Several studies have demonstrated the dominance of ST131, 
but often among isolates from small geographical regions or 
local studies and among a certain population or a convenience 
sample. A previous study that investigated the timing and tempo 
of the ST131 expansion in the United States that also used a 
sampling of E. coli isolates from the SENTRY Program reported 
a rate of 0.0% of ST131 among ESBL-producing E. coli in 2000. 
This rate increased to 45% in 2009 [79]. The study presented 
here showed a combined rate (UTI and BSI isolates) of 57% 
of ST131 in ESBL-producing E. coli in 2016 (data not shown). 
These data indicate that the proportion of ST131 increased sig-
nificantly among ESBL-producing E.  coli between 2000 and 
2009 in the United States and that it continues to increase, but 
perhaps at a slower pace. In addition, the ST131 rate reported 
here (57%) was very similar to that (56.8%) observed in a recent 
clinical trial, although the geographic origins of isolates were 
distinct [35]. Continuous surveillance over time should provide 
more granular information regarding the expansion of ST131 
and the proportion of genes belonging to CTX-M group 1 and 
group 9, as the latter group is increasingly being reported in the 
Asia-Pacific region [80].
Not many publications exist on the population genomic anal-
ysis of ESBL-producing K.  pneumoniae isolates in the United 
States. In contrast, much attention has been devoted to the 
emergence and dissemination of carbapenemase-producing 
K. pneumoniae, which has been largely attributed to the clonal 
expansion of a dominant genetic lineage, the clonal group (CG) 
258 (includes ST258 and single-locus variants ST11, ST512, 
ST340, and ST437) carrying carbapenemase-encoding genes 
[81–84]. The population structure of K.  pneumoniae isolates 
included here was more heterogeneous than that observed 
in E.  coli isolates, which emphasizes the opportunistic nature 
of these species. However, the results obtained among KPC-
producing K.  pneumoniae also reflect the well-known domi-
nance of CC258, as 84.6% of these isolates belonged to ST258.
Interestingly, the prevalence rates of E.  coli (11.6%–16.1%) 
and K. pneumoniae (11.0%–13.7%) isolates that met the MIC-
based screening criteria for ESBL production in this study 
(2016) were similar. Previous studies published in the late 
1990s reported rates of ESBL production among E. coli–causing 
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Figure 4. Distribution of β-lactamase-encoding genes detected in Escherichia coli ST131 causing bloodstream infection (A) and urinary tract infection (B). Chromosomal 
AmpC defined by the overexpression of AmpC; unknown defined as the lack of any extended-spectrum β-lactamase screened during the study. Abbreviations: BSI, blood-
stream infection; UTI, urinary tract infection.
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(0.4%–1.4%) and K.  pneumoniae–causing UTIs (4.2%–6.6%) 
[85] or K. pneumoniae–causing (5.8%) BSIs [86] in the United 
States that were much lower than those observed here. Another 
older study reported prevalence rates of ESBL-producing E. coli 
and K. pneumoniae of 3.3% and 7.6%, respectively, among iso-
lates causing various infection types in the United States (1997–
1999) [87]. It appears that the prevalence of the ESBL phenotype 
in K. pneumoniae used to be higher than its prevalence in E. coli. 
The data presented here suggest that the difference in ESBL phe-
notypes between species no longer exists and that it may, at least 
in part, be explained by the successful dissemination of E. coli 
ST131. No prevalent clonal type exists among K. pneumoniae, 
except for a small predominance of CC11 (28.3%) among UTI 
pathogens and CC307 (15.0%) among BSI isolates, which dif-
fers from E. coli.
NGS use will likely increase continuously, and its numerous 
applications depend on a proper bioinformatics workflow to 
obtain the required data in a report format that would be use-
ful, whether it relates to a single sample/pathogen or a greater 
collection of samples/isolates. JMI Laboratories has used NGS 
to characterize isolates originating from surveillance or clini-
cal trial studies, and the vast majority of the investigations have 
involved characterization of resistance mechanisms associated 
with a particular class of agents, any resistance genes, or epide-
miology typing. Some studies have also utilized NGS to investi-
gate the genetic context of resistance genes of interest [26, 88]. 
Also, importantly, storing digital data has become cheaper and 
more accessible with cloud-based options, and permanently 
storing digital sequencing data makes it possible for timeless ad 
hoc in silico analysis.
Furthermore, this study provides a benchmark for the dis-
tribution of β-lactamase genes and the population struc-
ture information obtained by NGS among the most common 
Enterobacteriaceae species responsible for BSIs and UTIs in 
US medical centers during the SENTRY Program for 2016. 
Coupling high-throughput genome sequencing with power-
ful bioinformatics tools can be useful to detect and monitor 
resistance genes and bacterial populations in surveillance pro-
grams and other investigations in different bacterial collections. 
Future studies that include isolates recovered from US and 
non-US medical centers during multiple years can contribute to 
the rapidly growing knowledge base of the distribution of resis-
tance/virulence genes and the evolution of bacterial popula-
tions within the context of clinically relevant human pathogens.
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